Colistimethate sodium lyophilized vials

Tobramycin sulfate is the sulfate salt of tobramycin, an aminoglycoside antibiotic active against gram-negative bacteria including most Enterobacteriaceae, Pseudomonas aeruginosa and a few gram-positive bacteria such as Staphylococcus aureus.

Indication: ...

Tyrothricin contains about 20% gramicidin and 80% tyrocidine and belongs to the family of polypeptide antibiotics. It is active against a variety of gram-positive bacteria, including Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus and bacteria causing diphtheria.
qq...

Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against diphtheroids, en...

Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against diphtheroid...

Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of Gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against diphtheroid...

Colistimethate sodium is a prodrug of colistin which is a mixture of polypeptide antibiotics active against gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.

Indication: Used in the treatment of patients with serious i...

Daptomycin is a lipopeptide antibacterial agent active against gram-positive bacteria.

Indication: Used in the treatment of complicated skin and skin structure/soft-tissue infections caused by susceptible isolates of gram-positive bacteria such as Staphylococcus au...

Daptomycin is a lipopeptide antibacterial agent active against gram-positive bacteria.

Indication: Used in the treatment of complicated skin and skin structure/soft-tissue infections caused by susceptible isolates of gram-positive bacteria such as Staphylococcus aureus...

Polymyxin B is a mixture of the sulfates of polypeptide antibiotics active against almost all gram-negative bacteria except the Proteus group.

Indication: Used in the treatment of patients with acute urinary, meningeal or blood-stream infections due to susceptible ...

US DMF Submitted & Under registration in Europe

Colistimethate sodium is a prodrug of colistin (polymyxin E) which is a mixture of polypeptide antibiotics active against gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. Indication: Used in the treatment of acute or chronic inf...

Product Pipeline

At Xellia, we work at the center of this challenge every day. Here is our perspective on what is at risk, why it matters, and what needs to change.


Antibiotics are the backbone of modern medicine. Without reliable access to them, surgical procedures carry greater risk, cancer treatments become more dangerous, and infections harder to manage. Yet the supply chains that deliver these essential medicines to hospitals all over the world are under growing strain and the consequences are already visible.

Xellia Pharmaceuticals is a specialty pharmaceutical company developing,manufacturing and commercializing anti-infective treatments againstserious and often life-threatening bacterial and fungal infections. Xellia isa world-leading trusted supplier of several important established antiinfectivedrugs, comprising active pharmaceutical ingredients as well asfinished dosage forms, where the majority are injectable drug products.Headquartered in Copenhagen, Denmark and owned by Novo HoldingsA/S, Xellia Pharmaceuticals has more than 1800 employees globally.From state-of-the-art manufacturing sites in the U.S., China, Denmarkand Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticalsexcels within innovative product development to deliver high qualityproducts to its customers.

We are more than an API company. We are built on long standing relationships that have stood the test of time. Why? Because for 120 years we have been developing the anti-infectives the world needs. But we are evolving and in the future, we won't be known just for anti-infectives. Our ambition? To be the leading global supplier of APIs across many therapeutic areas. 

Sustainability, the way we do everything else - honestly.

We make medicines that save lives. That's a responsibility we take seriously, in every direction — including the one that points toward the planet and the people we share it with.

Our 2025 Sustainability Report is out, and it tells a simple story: we're doing the work. Real numbers, real progress, real accountability — from our fermentation tanks in Copenhagen to our production lines in Budapest and Taizhou.

No greenwashing. No vague promises. Just a clear, honest look at where we stand and where we're headed — reviewed and signed off by our Executive Management team, because this matters enough to get right from the top.